Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | CSF1R | P07333 | 9/20 | 0.47 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.47 |
| ▸ | NTRK2 | Q16620 | 2/20 | 0.47 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.47 |
| ▸ | KIT | P10721 | 1/20 | 0.44 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.44 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.44 |
| ▸ | MAP4K3 | Q8IVH8 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21988922 | 0.81 | NPC1 (0.53) | NPC1RAB9ACSF1RNTRK1NTRK2 | |
| SCHEMBL21988883 | 0.80 | NPC1 (0.51) | NPC1RAB9ACSF1RNTRK1NTRK2 | |
| SCHEMBL21988774 | 0.80 | NPC1 (0.65) | NPC1RAB9ACSF1RNTRK1NTRK2 | |
| SCHEMBL22045233 | 0.77 | NPC1 (0.50) | NPC1RAB9ACSF1RNTRK1NTRK2 | |
| SCHEMBL21989002 | 0.77 | NPC1 (0.50) | NPC1RAB9ACSF1RNTRK1NTRK2 | |
| SCHEMBL21988876 | 0.76 | NPC1 (0.47) | NPC1RAB9ACSF1RNTRK1NTRK2 | |
| SCHEMBL21988985 | 0.76 | NPC1 (0.47) | NPC1RAB9ACSF1RNTRK1NTRK2 | |
| SCHEMBL21988703 | 0.74 | NPC1 (0.50) | NPC1RAB9ACSF1RNTRK1NTRK2 | |
| SCHEMBL21989018 | 0.72 | NPC1 (0.51) | NPC1RAB9ACSF1RNTRK1NTRK2 | |
| SCHEMBL23041150 | 0.72 | NPC1 (0.64) | NPC1RAB9ACSF1RNTRK1NTRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12103921-B2 | Chemical compounds | PFIZER INC. (US) | 2024-10-01 | — | — | US | disclosed |
| US-20230382892-A1 | Chemical Compounds | PFIZER INC. (US) | 2023-11-30 | — | — | US | disclosed |
| US-20230382892-A1 | Chemical Compounds | PFIZER INC. (US) | 2023-11-30 | — | — | US | disclosed |
| US-20230382892-A1 | Chemical Compounds | PFIZER INC. (US) | 2023-11-30 | — | — | US | disclosed |
| US-11702405-B2 | Chemical compounds | PFIZER INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-11702405-B2 | Chemical compounds | PFIZER INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-11702405-B2 | Chemical compounds | PFIZER INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20220348555-A1 | Chemical Compounds | PFIZER INC. (US) | 2022-11-03 | — | — | US | disclosed |
| EP-3886984-A1 | PYRAZOLES AS MODULATORS OF HEMOGLOBIN | Pfizer Inc. (US) | 2021-10-06 | — | — | EP | disclosed |
| US-11014908-B2 | Chemical compounds | PFIZER INC. (US) | 2021-05-25 | — | — | US | disclosed |
| US-11014908-B2 | Chemical compounds | PFIZER INC. (US) | 2021-05-25 | — | — | US | disclosed |
| US-20200172512-A1 | Chemical Compounds | PFIZER INC. (US) | 2020-06-04 | — | — | US | disclosed |
| US-20200172512-A1 | Chemical Compounds | PFIZER INC. (US) | 2020-06-04 | — | — | US | disclosed |
| WO-2020109994-A1 | PYRAZOLES AS MODULATORS OF HEMOGLOBIN | PFIZER INC. (US) | 2020-06-04 | — | — | WO | disclosed |
| WO-2020109994-A1 | PYRAZOLES AS MODULATORS OF HEMOGLOBIN | PFIZER INC. (US) | 2020-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200172512-A1 | Chemical Compounds | HBZ, HBB, HBS1L | NPC1 2812/4885RAB9A 1684/4885CSF1R 2914/4885 |
| US-11702405-B2 | Chemical compounds | HBZ, HBB, HBS1L | NPC1 2812/4885RAB9A 1684/4885CSF1R 2914/4885 |
| US-20230382892-A1 | Chemical Compounds | HBZ, HBB, HBS1L | NPC1 2812/4885RAB9A 1684/4885CSF1R 2914/4885 |
| US-12103921-B2 | Chemical compounds | HBZ, HBB, HBS1L | NPC1 2812/4885RAB9A 1684/4885CSF1R 2914/4885 |
| US-11014908-B2 | Chemical compounds | HBZ, HBB, HBS1L | NPC1 2812/4885RAB9A 1684/4885CSF1R 2914/4885 |
| US-20220348555-A1 | Chemical Compounds | HBZ, HBB, HBS1L | NPC1 2812/4885RAB9A 1684/4885CSF1R 2914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.